TegoScience Inc Asset Resilience Ratio
TegoScience Inc asset resilience ratio. TegoScience Inc (191420) has an Asset Resilience Ratio of 52.34% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of TegoScience Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of TegoScience Inc (2015–2025)
Asset resilience ratio of TegoScience Inc from 2015 to 2025. This chart shows how TegoScience Inc's Asset Resilience Ratio has changed over time. Read 191420 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down TegoScience Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of TegoScience Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩39.98 Billion | 52.34% |
| Total Liquid Assets | ₩39.98 Billion | 52.34% |
Asset Resilience Insights
- Very High Liquidity: TegoScience Inc maintains exceptional liquid asset reserves at 52.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
TegoScience Inc Industry Peers by Asset Resilience Ratio
Compare TegoScience Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GeneBioTech Co. Ltd
KQ:086060 |
Pharmaceuticals | 22.68% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 6.87% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 66.73% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 0.00% |
|
Aprogen Healthcare & Games Inc
KQ:109960 |
Pharmaceuticals | 6.55% |
TegoScience Inc Asset Resilience Ratio by Year (2015–2025)
TegoScience Inc asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for TegoScience Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 49.64% | ₩38.80 Billion ≈ $26.29 Million |
₩78.16 Billion ≈ $52.97 Million |
-2.42pp |
| 2024-12-31 | 52.06% | ₩27.34 Billion ≈ $18.53 Million |
₩52.52 Billion ≈ $35.59 Million |
+9.30pp |
| 2023-12-31 | 42.76% | ₩20.91 Billion ≈ $14.17 Million |
₩48.91 Billion ≈ $33.15 Million |
-0.67pp |
| 2022-12-31 | 43.43% | ₩22.31 Billion ≈ $15.12 Million |
₩51.36 Billion ≈ $34.81 Million |
+1.65pp |
| 2021-12-31 | 41.78% | ₩21.31 Billion ≈ $14.44 Million |
₩51.00 Billion ≈ $34.56 Million |
-3.79pp |
| 2020-12-31 | 45.58% | ₩22.97 Billion ≈ $15.57 Million |
₩50.40 Billion ≈ $34.16 Million |
-0.32pp |
| 2019-12-31 | 45.90% | ₩22.29 Billion ≈ $15.11 Million |
₩48.57 Billion ≈ $32.91 Million |
+22.22pp |
| 2018-12-31 | 23.67% | ₩11.26 Billion ≈ $7.63 Million |
₩47.56 Billion ≈ $32.23 Million |
+1.76pp |
| 2017-12-31 | 21.92% | ₩10.43 Billion ≈ $7.07 Million |
₩47.59 Billion ≈ $32.25 Million |
-23.31pp |
| 2016-12-31 | 45.22% | ₩20.19 Billion ≈ $13.68 Million |
₩44.64 Billion ≈ $30.25 Million |
+33.58pp |
| 2015-12-31 | 11.65% | ₩3.00 Billion ≈ $2.03 Million |
₩25.76 Billion ≈ $17.46 Million |
-- |
About TegoScience Inc
TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.